Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Krystal Biotech, Inc. (KRYS)
:KRYS
Holding KRYS?
Track your performance easily
KRYS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$107.50 - $219.34
Previous CloseN/A
Volume44.50K
Average Volume (3M)269.05K
Market Cap
$4.51B
Enterprise Value$4.86B
Total Cash (Recent Filing)$1.92M
Total Debt (Recent Filing)$1.84M
Price to Earnings (P/E)88.6
Beta1.29
Next Earnings
Mar 03, 2025EPS Estimate
1.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.77
Shares Outstanding28,760,548
10 Day Avg. Volume190,697
30 Day Avg. Volume269,054
Standard Deviation0.15
R-Squared0.09
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)19.02
Price to Cash Flow (P/CF)19.50
P/FCF Ratio19.90
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue20.13
Enterprise Value/Gross Profit102.14
Enterprise Value/Ebitda29.94
Forecast
1Y Price Target
$210.43Price Target Upside34.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Krystal Biotech News
PremiumCompany Announcements
Krystal Biotech Reports Positive Results for KYANITE-1 Study
PremiumCompany Announcements
Krystal Biotech Reports Promising Results for Genetic Medicine
PremiumCompany Announcements
Krystal Biotech Reports Strong Q3 2024 PerformanceBulls Say, Bears Say
Bulls Say
Clinical Trial ExpansionThe expansion into combination cohorts with Keytruda or Keytruda + SoC chemotherapy should help clarify the potential market share ‘707 can capture and its place in the treatment paradigm.
Inhaled Platform PotentialThe HSV platform's early data reduces risk, indicating potential in Krystal’s inhalation-based delivery method.
Safety ProfileThe safety profile of ‘707 in the NSCLC population is strong, with most adverse events being mild to moderate and no grade 4+ adverse events recorded.
Bears Say
Management GuidanceManagement guided to a continued downward trend on compliance.
Product Launch ImpactThe maturing of the Vyjuvek launch is pressuring the stock.
Treatment Efficacy‘707 responses in NSCLC look comparable with common treatment options but are slightly lacking compared to some targeted therapies.
---
Ownership Overview
Currently, No data available
---
KRYS FAQ
What was Krystal Biotech, Inc.’s price range in the past 12 months?
Krystal Biotech, Inc. lowest stock price was $107.50 and its highest was $219.34 in the past 12 months.
What is Krystal Biotech, Inc.’s market cap?
Krystal Biotech, Inc.’s market cap is $4.51B.
When is Krystal Biotech, Inc.’s upcoming earnings report date?
Krystal Biotech, Inc.’s upcoming earnings report date is Mar 03, 2025 which is in 53 days.
How were Krystal Biotech, Inc.’s earnings last quarter?
Currently, no data Available
Is Krystal Biotech, Inc. overvalued?
According to Wall Street analysts Krystal Biotech, Inc.’s price is currently Undervalued.
Does Krystal Biotech, Inc. pay dividends?
Krystal Biotech, Inc. does not currently pay dividends.
What is Krystal Biotech, Inc.’s EPS estimate?
Krystal Biotech, Inc.’s EPS estimate is 1.21.
How many shares outstanding does Krystal Biotech, Inc. have?
Krystal Biotech, Inc. has 28,760,548 shares outstanding.
What happened to Krystal Biotech, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Krystal Biotech, Inc.?
Currently, no hedge funds are holding shares in KRYS
---
Krystal Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$210.43 (34.87% Upside)
$210.43 (34.87% Upside)
Blogger Sentiment
Bullish
KRYS Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
23.89%
12-Months-Change
Fundamentals
Return on Equity
5.91%
Trailing 12-Months
Asset Growth
24.29%
Trailing 12-Months
Company Description
Krystal Biotech, Inc.
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.
---
KRYS Stock 12 Month Forecast
Average Price Target
$210.43
▲(34.87% Upside)
Technical Analysis
Best Analysts Covering KRYS
1 Year
1 Year Success Rate
13/15 ratings generated profit
1 Year Average Return
+46.17%
reiterated a buy rating 2 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +46.17% per trade.
---